Discovery of novel InhA inhibitors through structural bioinformatics and machine learning-driven QSAR screening of natural products
Open Access
- 12 January 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in Biology Methods and Protocols
- Vol. 11 (1)
Abstract
Tuberculosis (TB) persists as a formidable global health challenge, particularly due to the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) variants that limit the effectiveness of existing therapies. These variants limit therapeutic options, prolong treatment duration and increase the risk of treatment failure. Additionally, the antitubercular drug discovery remains relatively limited; moreover, the rise in drug-resistant strains necessitates the need to identify and develop novel drug candidates that can overcome these resistance patterns. This study aims to design novel InhA inhibitors that can bind to and inhibit InhA and circumvent the resistance pathway in the KatG enzyme of Mycobacterium tuberculosis. We sourced an extensive library of 276 518 natural products from the LOTUS database and screened the compounds through a series of rigorous computational approaches such as drug-likeness filtration, molecular docking, MM-GBSA analysis, and ADMET prediction. We developed a machine learning model using a Message Passing Neural Network (MPNN). The MPNN was trained to predict bioactivity profiles of 31 597 natural products against the InhA enzyme. Molecular dynamics simulations further confirmed the stability of these interactions over 100-nanoseconds. Out of the screened compounds, four novel drug candidates exhibited strong binding affinities with binding energies of −12.204 kcal/mol, −11.926 kcal/mol, −11.624 kcal/mol, and −11.548 kcal/mol, respectively, surpassing the co-crystallized ligand (−8.895 kcal/mol), and the standard drug, Isoniazid (−12.204 kcal/mol). The top hit molecules demonstrated high and considerable structural stability during molecular dynamics simulations. Additionally, the pharmacokinetic profile of LTS0161715 exhibited low toxicity. positioning LTS0161715 for further investigation. These research findings elucidate the potential of direct InhA inhibitors, particularly LTS0161715, as a promising drug candidate for anti-tubercular drug development, while also highlighting the need for further optimization to enhance safety and efficacy.Keywords
This publication has 65 references indexed in Scilit:
- HPLC characterization, molecular docking, QSAR and molecular dynamics simulation of Alstonia boonei phytochemical analogs as potent 5-alpha reductase inhibitorsDiscover Chemistry, 2025
- Machine learning-based QSAR and structure-based virtual screening guided discovery of novel mIDH1 inhibitors from natural productsJournal of Computer-Aided Molecular Design, 2025
- Protein–ligand molecular dynamics simulation (PL-MDS), ADMET analyses, and bioactivity studies of phytochemicals from Aloe Vera: an In-Silico novel antidiabetics drug discovery effortDiscover Chemistry, 2025
- Evaluation of Phytochemicals for Anti‐Tubercular Potential Targeting Enoyl‐Acyl Carrier Protein Reductase (InhA): An In Silico ApproachChemistrySelect, 2024
- Development and test of highly accurate endpoint free energy methods. 2: Prediction of logarithm of n‐octanol–water partition coefficient (logP) for druglike molecules using MM‐PBSA methodJournal of Computational Chemistry, 2023
- Molecular Dynamics Simulations: Concept, Methods, and Applications2022
- Molecular docking studies, molecular dynamics and ADME/tox reveal therapeutic potentials of STOCK1N-69160 against papain-like protease of SARS-CoV-2Molecular Diversity, 2020
- NMR quality control of fragment libraries for screeningJournal of Biomolecular NMR, 2020
- Antibiotic resistance mechanisms in M. tuberculosis: an updateArchives of Toxicology, 2016
- N‐Benzyl‐4‐((heteroaryl)methyl)benzamides: A New Class of Direct NADH‐Dependent 2‐trans Enoyl–Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular ActivityChemMedChem, 2016